EC approves Cabometyx tablets to treat advanced RCC following VEGF-targeted therapy
US biopharmaceutical firm Exelixis discovered and developed Cabometyx, which is claimed to be the first and only therapy approved in the European Union to demonstrate enhanced overall survival,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.